Antibodies reactive with human carcinomas
CA 2020247 C · Owner: Schreiber, George J. · Inventors: Bruce, Kim F.; Hellstrom, Karl E.; Hellstrom, Ingegerd
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to novel antibodies reactive with human carcinoma cells. More particularly the, antibodies of the invention include: a murine monoclonal antibody, BR96; a human/murine chimeric antibody ChiBR96; and, a F(ab')2 fragment of BR96. These antibodies are reactive with a cell membrane antigen on the surface of human carcinomas. The antibodies display a high degree of selectivity for carcinoma cells and possess the ability to mediate ADCC and CDC activity. In addition, the antibodies of the invention internalize within the carcinoma cells to which they bind and are therefore particularly useful for therapeutic applications, for example, as the antibody component of …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 29, 1990 and granted April 30, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 29, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 29, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.